1. How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Cutaneous Squamous Cell Carcinoma Is a Spectrum of Disease

5. Case 1 Harriet

6. Case 1 Harriet (cont)

7. What Is Locally Advanced cSCC?

8. Staging cSCC

9. High-Risk cSCC

10. Widespread Local cSCC Is High-Risk

11. Widespread Local cSCC Is High-Risk (cont)

12. Widespread Local cSCC Is High-Risk (cont)

13. Treatment of Advanced cSCC

14. Cetuximab First-Line Monotherapy in cSCC

15. Postoperative ChemoRT vs RT in cSCC

16. Case 2 Dominic

17. Case 2 Dominic (cont)

18. Who Would Be a Candidate for Immunotherapy?

19. Case 2 Dominic (cont)

20. Phase 2 Study of Pembrolizumab in Metastatic cSCC Study Design

21. Phase 2 Study of Pembrolizumab in Metastatic cSCC Results

22. Phase 2 Study of Cemiplimab in Metastatic cSCC Study Design

23. Phase 2 Study of Cemiplimab in Metastatic cSCC Results

24. Phase 2 Study of Cemiplimab in Metastatic cSCC Safety Data

25. Cemiplimab in cSCC Phase 1 Expansion Cohorts

26. Interpretation of Emerging Data

27. Question & Answer Session

28. Q&A

29. Q&A (cont)

30. Q&A (cont)

31. Q&A (cont)

32. Conclusions and Key Takeaways

33. Abbreviations

34. Abbreviations (cont)